Chemotherapy for medulloblastoma/primitive neuroectodermal tumors of the posterior fossa

✍ Scribed by Dr Roger J. Packer

• Publisher: John Wiley and Sons
• Year: 1990
• Tongue: English
• Weight: 634 KB
• Volume: 28
• Category: Article
• ISSN: 0364-5134
• DOI: 10.1002/ana.410280615

✦ Synopsis

Abstract

Chemotherapy has only marginal efficacy in adult malignant brain tumors. In contrast, drug therapy is considerably more effective in medulloblastoma/primitive neuroectodermal tumors (MB/PNET) of the posterior fossa, the most common childhood primary central nervous system tumor. At the time of disease recurrence, a variety of different single agents and drug combinations result in tumor shrinkage and increased survival. The addition of chemotherapy to standard radiotherapy improves the rate and length of disease‐free survival for those children with MB/PNET who have the most extensive tumors at diagnosis. It remains to be determined which drug or drug combinations are the most effective in MB/PNET, and which patients are most likely to benefit from chemotherapy. Chemotherapy may be useful to reduce or, in selected cases, obviate the need for radiotherapy and reduce treatment‐related sequelae.